SLC35D3 Activators
SLC35D3 Activators are a collection of chemical compounds that, through distinct mechanisms, amplify the functional activity of SLC35D3. Forskolin, by increasing intracellular cAMP through direct stimulation of adenylyl cyclase, enhances the SLC35D3 activity via PKA-dependent phosphorylation. Similarly, IBMX raises cAMP levels by broadly inhibiting phosphodiesterases, indirectly facilitating SLC35D3 activity by sustaining PKA-mediated signaling. Epigallocatechin gallate, known for its kinase inhibition properties, and Curcumin, which modulates various signaling proteins, both have the potential to indirectly promote SLC35D3 activity by modifying downstream signaling effects that intersect with SLC35D3's functional pathways. Phosphodiesterase inhibitors like Sildenafil, Rolipram, Zaprinast, Anagrelide, Cilostamide, Milrinone, and Vinpocetine elevate cAMP or cGMP, thereby enhancing SLC35D3 activity through PKA or PKG pathways, with each inhibitor targeting a specific phosphodiesterase isoform to augment the intracellular signaling cascade that culminates in SLC35D3 activation.
The SLC35D3 protein, integral to various cellular processes, is further influenced by compounds that boost secondary messenger systems. Indomethacin, though primarily known as an anti-inflammatory agent, affects cAMP-related signaling which could lead to indirect enhancement of SLC35D3 activity by altering kinase signaling dynamics.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin directly stimulates adenylyl cyclase, increasing the production of cyclic AMP (cAMP) which can enhance SLC35D3 activity by phosphorylation through PKA-dependent signaling pathways. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX acts as a non-specific inhibitor of phosphodiesterases, leading to increased cAMP levels, which can indirectly enhance SLC35D3 activity through PKA signaling. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Epigallocatechin gallate acts as an antioxidant and has been found to inhibit certain protein kinases, potentially altering signaling pathways that could enhance SLC35D3 activity. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin modulates various signaling proteins including kinases, which could lead to the enhanced activity of SLC35D3 by affecting these protein's downstream effects. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram, a selective PDE4 inhibitor, increases cAMP levels thereby potentially enhancing SLC35D3 activity through the cAMP/PKA signaling axis. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Zaprinast inhibits PDE5 and PDE10 leading to increased cAMP and cGMP levels which may enhance SLC35D3 activity via PKA and PKG pathways, respectively. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $147.00 | ||
Anagrelide inhibits PDE3, thus raising cAMP levels which could indirectly enhance SLC35D3 activity through activation of PKA-dependent pathways. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $90.00 $350.00 | 16 | |
Cilostamide is a selective PDE3 inhibitor, which could increase cAMP levels, enhancing SLC35D3 activity by influencing PKA signaling pathways. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $162.00 $683.00 | 7 | |
Milrinone selectively inhibits PDE3, leading to higher cAMP levels and potentially enhancing SLC35D3 activity through cAMP-dependent PKA signaling. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $28.00 $37.00 | 18 | |
Indomethacin affects various signaling pathways, including those modulated by cAMP, which could indirectly enhance SLC35D3 activity by modifying protein kinase signaling. | ||||||